Menu
Washingtoner
  • Home
  • Business
  • Real Estate
  • Technology
  • Home
  • Pets
  • Security
  • Shipping
  • Health
Washingtoner

NRx Pharmaceuticals NRXP: Prominently Featured in Psychiatrist.com; Article Titled "How NRx Could Upend the Fight Against Depression and Suicide"
Washingtoner/10268863

Trending...
  • InventHelp Inventor Develops New Accessory for Fishermen (TGR-242)
  • Tampa-Based Digital Marketing Agency Launches New Website to Help Local Businesses Grow Online
  • myb.day Launches New Birthday Gift Shop Filled With Personalized Surprises
NRXP NASDAQ NRXP 2 NRXP 3 NRXP 4 NRXP 5 Corporate Ads
Substantial Funding Agreements, Debt Resolution and Successful Clinical Trial Progress Towards Accelerated Drug Approval

RADNOR, Pa. - Washingtoner -- NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain

NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

NRx Pharmaceuticals, Inc. Featured on Psychiatrist.com: "How NRx Could Upend the Fight Against Depression and Suicide"

In a high recognition biopharma industry feature, NRXP has been profiled in an article published on Psychiatrist.com.  This prominent outlet is the home of the Journal of Clinical Psychiatry, the official journal of the American Society of Clinical Psychopharmacology.

The article, entitled "How NRx Could Upend the Fight Against Depression and Suicide," can be found at this direct link: https://www.psychiatrist.com/news/how-nrx-could-upend-the-fight-against-depression-and-suicide/.

More on Washingtoner
  • ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
  • Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
  • Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
  • Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
  • Cybersecurity is Protecting Your Personal Information and Your Portfolio

The author notes:

"Clinical relevance: NRX Pharmaceuticals is developing a pair of promising new treatments for bipolar depression and suicidal ideation."

"NRX-101 is a twice-daily fixed-dose oral combination of D-cycloserine and lurasidone the company developed to treat suicidal treatment-resistant bipolar depression. Researchers found this combination showed a higher efficacy than lurasidone alone for reducing akathisia and suicidality."

"NRX-100 is a proprietary preservative-free formulation of IV ketamine. Researchers have studied it as a treatment for acute suicidal crises in depression."

Nearly 4 million Americans planned suicide in 2022, with estimates suggesting that two-thirds of cases are associated with a mood disorder.

NRX-101 is an oral, fixed-dose combination of D-cycloserine and lurasidone being developed to treat treatment-resistant bipolar depression with suicidality or akathisia.

NRX-100 is an IV ketamine formulation being studied as a treatment for acute suicidal crises in all forms of depression, including bipolar depression.

The potential of these two NRXP therapies is monumental.  Bipolar disorder presents a significant global health challenge, mostly because of its close ties to higher suicide risk during depressive episodes.  Suicidal Depression affects millions of people every year; a pharmacologic treatment is a critical need.

The lack of FDA-approved pharmacological treatments targeting suicidal and bipolar depression with suicidality or akathisia in today's market underscores the need for more innovative therapies. And, if approved, these new NRXP treatments would be the first FDA-approved pharmaceutical regimens developed to treat these in patients struggling with suicidal behavior, ideation, or depression.

It's not an overstatement to say that NRXP could not only improve the quality of life for millions of people. It would also significantly cut the suicide rates among those affected.

More on Washingtoner
  • L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
  • Spokane: Flags Lowered for Justice Owens
  • Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
  • Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
  • Space Resources Company Interlune Unveils Full-Scale Prototype of Excavator for Harvesting Helium-3 from the Moon

Participation at New York Global Investment Conference

NRXP
has been featured at an important Global Investment Conference held in New York City on September 9-11, 2024.

Investors can listen to the full NRXP presentation via the following link www.hcwevents.com/annualconference

Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics

NRXP
has also announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, NRXP has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. NRXP anticipates potential operations in the United States, France, and the United Kingdom.

This non-dilutive acquisition funding is in addition to the over $60 million in potential equity funding previously offered upon public listing of NRXP spin-off HOPE Therapeutics shares on a public exchange.

To Review $NRXP visit: https://www.nrxpharma.com/ or https://compasslivemedia.com/case-study/nrx-pharmaceuticals/

Media Contact


Company Name: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
Contact Person: Matthew Duffy, Chief Business Officer

Company Website: https://www.nrxpharma.com/
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Home Country: United States

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website

Contact
Corporate Ads
***@gmail.com


Source: Corporate Ads

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • NASDAQ Uplisting for Higher Market Exposure and Wide Corporate Benefits to AI Boosted Marketing Company On Track Towards $1 Billion Revenue by 2027
  • Congressional Men's Health Caucus Shows Bipartisan Consensus and Focus on Prevention, Mental Health, and Closing the Lifespan Gap
  • DuoKey, Axiomtek and Blue Edge Network Partner to Enhance Smart Cities with Privacy-Preserving Urban Safeguarding and Fleet Management
  • PNNL's Grid Storage Launchpad honored with 2025 BCI Innovation Award
  • Austin Keen Joins WakeFX RopePal as Official Brand Ambassador
  • Bonelli Systems Expands Managed IT Services Nationwide, Leveraging Microsoft Azure Expertise
  • $4.3 Million Patent Application Waiver Fee Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression & PTSD: NRX Pharma
  • Whistleblower Claims Dental Patient Deaths Likely Due to Book Ban
  • xREnergy up as much as +3,094,634% on first day listed on the XRP Ledger. Ticker : $XRE
  • Psychiatry's Legacy of Racism and Coercion Highlighted in Restraint Deaths
  • New Book 'Cybersecurity Leadership' Guides SME Leaders to Make Smart, Strategic Security Decisions
  • "Stop scrolling and start watching" - Beloved film recommendation site Criticker gets a major makeover
  • Green Energy Solar Expands with New Offices in Port St. Lucie, West Palm Beach, and Orlando
  • IGT PlaySports Introduces World-Class Retail Sports Betting to Silver Reef Casino Resort
  • Events by Dubsdread Expands Services to The Venue at Lake Lily
  • London Gala Emphasizes Trade, FDI and Ongoing Cooperation
  • Sahit Muja Launches Trillion-Dollar Green Revolution with 10 Groundbreaking Cryptos
  • Free and Low-Cost Dental Care Now Available in London Through the Canadian Dental Care Plan (CDCP)
  • Garden State Gay Socials Turns One: 1st Birthday Celebration for Gay Men Who Want Real Connection
  • Sea Fox® 368X "Extreme Edition" by Black Label Marine Group Celebrates 5 Years of the Commander Legacy
_catLbl0 _catLbl1

Popular on Washingtoner

  • 11th annual Florida Blueberry Festival April 26 & 27, 2025 - 141
  • HR Tech Awards Program Celebrates 6th Year: Showcases Top Hiring, Talent, and HR Technologies - 122
  • People & Stories/Gente y Cuentos Announces New Board Leadership & Corporate Partnership Initiative - 114
  • Mission 3A Establishes Healthcare Advisory Board with Addition of Industry Leaders Patrick Fisher, Kevin Cordell, and Dr. Greg Berlet - 111
  • PebblePad Welcomes Justin Reilly as New CEO to Drive Innovation and Growth - 109
  • American Mensa Welcomes 7-Year-Old Savannah Boy - 109
  • Village Vapes and Cooking 4 Autism Announce Inaugural Partnership at MEGA 420 EVENT
  • Axiros Confirms Continued Compliance with ISO/IEC 27001:2022 After Surveillance Audit
  • S2C and Andes Technology Announce FPGA-Based Prototyping Partnership to Accelerate Advanced RISC-V SoC Development
  • The Great Junk Hunt Returns to Puyallup – A Vintage Shopping Experience Like No Other!

Similar on Washingtoner

  • ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
  • Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
  • Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
  • Cybersecurity is Protecting Your Personal Information and Your Portfolio
  • The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
  • $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
  • SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
  • ImagineX, in Collaboration with Qualys, Launches New mROC Services to Transform Enterprise Cyber Risk Management
  • Jay Tapp was named Managing Director in British Columbia
  • 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
Copyright © 2025 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute